Loading
CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Olaparib.
In plain words · CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
CBLC (E3 ubiquitin-protein ligase CBL-C) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer.
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome.
No product in this corpus aims at CBLC yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CBLC: RNA tissue enhanced (esophagus 38 nTPM, intestine 48 nTPM, skin 1 41 nTPM); high antibody staining in 3 normal tissues; highest cancer staining renal cancer (7 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CBLC tissue; Open Targets ENSG00000142273 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Kim et al, Gene, 1999, "Molecular cloning and characterization of a novel cbl-family gene, cbl-c". Source.
Sources: HGNC HGNC:15961 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9ULV8 (protein name, function text, keywords and locations (REST API)); CIViC gene CBLC (1 evidence items, 0 assertions, 1 variants; diseases: Breast Carcinoma (GraphQL API, CC0))
Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Functionally coupled with the E2 ubiquitin-protein ligases UB2D1, UB2D2 and UB2D3. Regulator of EGFR mediated signal transduction; upon EGF activation, ubiquitinates EGFR. Isoform 1, but not isoform 2, inhibits EGF stimulated MAPK1 activation. Promotes ubiquitination of SRC phosphorylated at 'Tyr-419'. In collaboration with CD2AP may act as regulatory checkpoint for Ret signalling by modulating the rate of RET degradation after ligand activation; CD2AP converts it from an inhibitor to a promoter of RET degradation; the function limits the potency of GDNF on neuronal survival. Locus 19q13.32 (HGNC).
RNA: tissue enhanced (esophagus 38 nTPM, intestine 48 nTPM, skin 1 41 nTPM), detected in many normal tissues.
Medium: Adrenal gland, Duodenum, Fallopian tube, Gallbladder, Kidney, Liver, Small intestine.
Medium only: breast cancer, cervical cancer, colorectal cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CBLC" OR ABSTRACT:"CBLC" OR TITLE:"Cbl proto-oncogene C" OR ABSTRACT:"Cbl proto-oncogene C" OR TITLE:"E3 ubiquitin-protein ligase CBL-C" OR ABSTRACT:"E3 ubiquitin-protein ligase CBL-C" OR TITLE:"CBL-3" OR ABSTRACT:"CBL-3" OR TITLE:"CBL-SL" OR ABSTRACT:"CBL-SL" OR TITLE:"RNF57" OR ABSTRACT:"RNF57") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBLC, not a curated reading list.